| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 9, 2011
MINNEAPOLIS, Nov 09, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today reported results of an retrospective study available online and in an upcoming print edition of the Journal of Spinal...
-
Nov 8, 2011Pooled Data Analyses to Be Presented at TCT 2011 Demonstrate Heart Device's Consistently Positive Performance Across Multiple Clinical Studies
SAN FRANCISCO, Nov 08, 2011 (BUSINESS WIRE) -- Currently under review by the U.S. Food and Drug Administration (FDA), the Resolute(R) drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT)...
-
Nov 8, 2011Final Five-Year Follow-up of Randomized ENDEAVOR IV Trial Shows Durable Safety and Efficacy of Endeavor DES, with Comparatively Lower Rates of Cardiac Death/Myocardial Infarction and Very Late Stent Thrombosis
SAN FRANCISCO, Nov 08, 2011 (BUSINESS WIRE) -- New research findings released at TCT 2011 show that the Endeavor(R) zotarolimus-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT) outperformed...
-
Oct 31, 2011Assurant(R) Cobalt Iliac Stent Features Novel Alloy and Modular Design; Augments Company's Peripheral Portfolio with Balloon-Expandable Option
MINNEAPOLIS, Oct 31, 2011 (BUSINESS WIRE) -- Advancing the treatment of peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced approval by the U.S. Food and Drug Administration...
-
Oct 28, 2011A Critical Step Toward the Development of an Artificial Pancreas, Low Glucose Suspend Aims to Reduce Hypoglycemia
MINNEAPOLIS, Oct 28, 2011 (BUSINESS WIRE) -- In our continued commitment to develop an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA)...